Back to search

The University of Edinburgh

Presence of aldehyde dehydrogenase-high cell subpopulations in ovarian carcinoma and their sensitivity to nifuroxazide

Abstract

dc:description.abstract

High grade serous ovarian carcinoma (HGSOC) is the most common form of ovarian cancer, with 7,500 new cases being diagnosed in the UK every year. Despite key breakthroughs in the treatment of HGSOC in recent years, the long term survival rates of these patients remain low and many patients will experience relapse following first line therapy. Therefore, further research into novel therapeutic targets is greatly needed to improve patient prognosis, particularly for patients with relapsed and metastasised disease who have limited treatment options. Aldehyde dehydrogenases (ALDH) are a well-established marker of the cancer stem-like cell (CSC) state – a cell population associated with tumourigenicity and chemoresistance. This cell population has been identified in HGSOC as well as numerous other cancer types. Targeting ALDHHigh cells may represent a novel strategy for patients unresponsive to current therapies, as this may kill the cells responsible for tumour persistence. Previous work by Sarvi et al. (2018) showed that the 5-nitrofuran pro-drug nifuroxazide (NAZ) can selectively target and induce apoptosis in ALDH1High cells in melanoma, both in vitro and in vivo. Based on these findings, I aim to investigate whether NAZ shows similar specific cytotoxic effects in HGSOC, in which ALDH1High CSCs have previously been identified. Using cell culture techniques and bioinformatic analysis of patient data, I showed that ALDHHigh cell subpopulations are present in HGSOC, both in vitro and in patient tumour sections. These have CSC phenotypes, as illustrated in colony formation assays, unlike ALDHLow cells of the same line. Gene expression analysis shows a specific 11-fold upregulation of the ALDH1A3 isoform in ALDHHigh OVCAR-8 cells. Subsequent CRISPR knock-out studies showed that ALDH1A3 is involved in both colony formation and sensitivity to NAZ. Therefore, we infer that the ALDHHigh phenotype is a direct result of high ALDH1A3 activity in these cells. I then tested the efficacy of NAZ in vitro by observing cellular responses to the drug in bulk HGSOC cell lines using 2-D and 3-D culture techniques, as well as in isolated ALDHHigh cell subpopulations identified using the FACS-based ALDEFLUOR assay. I found these ALDHHigh cells to be sensitive to NAZ treatment in a dose-dependent manner in 3-D in vitro colony formation assays. Finally, I developed a xenotransplantation mouse model of metastatic HGSOC, and used this to test the effect of NAZ on tumour growth rates in vivo. Although we found no significant difference in the growth of NAZ-treated versus untreated tumours, it may be that NAZ is successfully targeting a small subpopulation of ALDH1A3High cells within the tumour, and could be utilised in future in combination with first line therapeutic agents. In conclusion, I found that ALDH1A3High CSCs play a functional role in HGSOC and are sensitive to cytotoxic treatment with NAZ in vitro, paving the way for further understanding of the ALDHHigh cell state as a novel therapeutic target.

Degree

thesis:*
Grantor dc:publisher
The University of Edinburgh
Year dc:date.issued
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Massoud, Zahra
Advisors dc:contributor.advisor
  • Patton, Elizabeth
  • Gourley, Charlie

Subjects

dc:subject × 9

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Edinburgh
Base URL
era.ed.ac.uk/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Massoud, Zahra. Presence of aldehyde dehydrogenase-high cell subpopulations in ovarian carcinoma and their sensitivity to nifuroxazide. The University of Edinburgh, 2023. https://hdl.handle.net/1842/40798